Nice read

The market needs to see improved performance from the core business for shares to go significantly higher.
The market needs to see improved performance from the core business for shares to go significantly higher.
seekingalpha.com

I think the COVID Rayalde is not til May however I thought the phase 2 Rayalde results are suppose to be announced in the first quarter 2021?

What's the next announcement other than earnings will move the stock? I think we should see top line results with Rayalde phase 2 vitamin D4-5?

Any thoughts? Can't wait for Somotrogan!! in October

Nice find!! Remember we have data from Rayalde for vitamin D5 this quarter and Covid19 anytime!! let's hammer the shorts!!

Prior short was 104,770 Million now 102,550 Million

loo
View

Daily Short Sale Volume
View

Short Interest Ratio (Days To Cover)
12.0

Short Percent of Float
25.34 %

Short % Increase / Decrease
-2 %

Short Interest (Current Shares Short)
102,550,000

Shares Float
404,660,000

Short Interest (Prior Shares Short)

looks like 2 Million shares covered

Degenerate That's exactly the way I feel the big pop will be either Rayalde or Somotrogen second quarter with japan. I did talk to the company about why they do not released more PR's there answer was they don't want the competition knowing what contracts they are getting and trying to under cut them?? Take it for what it's worth

Here are 10 stocks that trade under $10 with large short percentages that could be short squeeze candidates:
Clovis Oncology Inc (NASDAQ: CLVS) is a biotechnology company. Currently, 42% of the float is short.
Senseonics Holdings, Inc. (NYSE: SENS) is a medical technology company; 34% of its float is traded short.
VBI Vaccines Inc. (NASDAQ: VBIV) develops vaccines for adults, children and newborns; 20% percent of the float is short.
Naked Brand Group Ltd (NASDAQ: NAKD) sells intimate, swimwear and apparel, and 33% of its float is short.
Precigen Inc (NASDAQ: PGEN) is a biotechnology company; 35% of its float is short.
Opko Health, Inc. (NASDAQ: OPK) is a pharmaceutical and diagnostics company, with 26% of its float short.
Lannett Company, Inc. (NYSE: LCI) is a generics pharmaceutical company; 25% of its float is short.
Dyanvax Technologies Corporation (NASDAQ: DVAX) is a biotechnology company that is seeing 24% of its float traded short.
United Microelectronics Corp (NYSE: UMC) is a semiconductor company that makes products for companies like Advanced Micro Devices, Inc. (NASDAQ: AMD) and Xilinx Inc (NASDAQ: XLNX). The company is seeing 21% of its float traded short.
TherapeuticsMD Inc (NASDAQ: TXMD) is a pharmaceutical company targeting women, and 25% of its float is short.

Hopefully It's OPK turn


10 Short Squeeze Candidates Under $10

Great news

https://www.opko.com/investors/news-events/press-releases/detail/422/new-drug-application-submitted-to-pmda-in-japan-for

OH OH Here we go!!!

https://www.reddit.com/r/Shortsqueeze/comments/l5pxrl/opko_health_opk_great_short_squeeze_target_for/

Just go to www.reddic.com sign in and you need to give a username and password than they will send you an email to make sure it's your email and you are set. Just give all the information of OPK being profitable ect and also mention why would theses shorts short a stock that save lives?? let all spread the word!! there is close to 30% short

WE should all join reddit and post OPK news releases they are actually profitable and a really good story with Bio-Reference, Somatrogon and Rayaldee?

One of the problems with OPK is there are to many shareholders that complain about the stock price and blame management and BOD's for the price being so low. We have an opportunity for a short squeeze so DON"T SELL. Those who do sell can't complain. This board is good buy way to many stupid shareholders. Look at GME smart shareholders.

I am a shareholder and know someone that knows this company inside and out and actually he is a really good stock trader and is very frustrated with OPK as he knows the upside and thinks the price should be at least $8 a share based on the company being profitable the last 2 quarters and going to be profitable the 4th quarter and the other drugs in the pipeline. I was not going after you just venting my frustration on SAIN Capital so the intent was not on you I just responded because the article GO OPK.

First off Sian Capital are losers. OPK management gave guidance while the company was just a few weeks in that quarter so they did what most companies do and that is under promise and over deliver. Sian the losers give there guidance when the quarter is over. Every shareholder wants there company that there are invested in to beat there own guidance. Every time OPK starts to get momentum those LOSERS come out with some letter by the way I have never received it??? I know a guy that emailed SIAN after there first letter and asked them some questions like give me prove of your shares?? and at what price$$ I think we should all call them out on there past record? Why if they are so smart and have all the answers didn't they buy the stock at $1.50???

More Testing Buffalo Bills Win

Here we go

Things to Expect from OPKO Health in 2021
It's the perfect time for a wealthy CEO to ride off into the sunset.
Jason Hawthorne
Jason Hawthorne
(TMFjbonefish)
Jan 6, 2021 at 7:11AM
OPKO Health (NASDAQ:OPK) was one of the many diagnostic testing companies that saw volumes increase dramatically in 2020, with revenue up 49% through the first nine months of 2020. Below are three things to expect from the company in 2021.

A crystal ball with 2021 inside of it.
IMAGE SOURCE: GETTY IMAGES

1. Riding the wave
Despite talk of flattening the curve in the early months of the pandemic, cases have continued to spread and testing has followed. With reported coronavirus cases in the U.S. recently averaging over 200,000 every day, expect test volumes and revenue to continue climbing until vaccines are broadly distributed.

Quarter COVID Tests Testing Revenue YoY Growth (Decline)
Q1 2020 700,000 $170.8 million (5%)
Q2 2020 2.53 million $251 million 41%
Q3 2020 3.8 million $382.5 million 111%
DATA SOURCE: OPKO HEALTH. YOY = YEAR OVER YEAR.

2. Leaving the past behind
When OPKO purchased BioReference Labs for $1.47 billion in 2015, the former had only $91 million in annual revenue compared to $832 million for the company it bought. More than five years later, the services revenue (another name for testing) over the past 12 months remains near 90% of total sales, and neither business has shown much growth. Trailing-12-month revenue for the services and products units (products are the pharmaceuticals) were $982 million and $121 million, respectively. OPKO might sell its pharmaceutical assets and complete the transformation into solely a diagnostics business.

3. For sale, by owner
OPKO's $2.8 billion market cap is nearly three times what it was in March, and selling the company now would maximize value to shareholders. CEO Phillip Frost is one of the wealthiest people in the world at 84 years old. After 13 years as Chairman and CEO of OPKO, it's possible that Frost could take advantage of the timing and exit the business through a sale to begin his retirement this year.


Should you invest $1,000 in OPKO Health, Inc. right now?
Before you consider OPKO Health, Inc., you'll want to hear this.

Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now... and OPKO Health, Inc. wasn't one of them.

The online investing service they've run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

5 Stocks Under $49

We hear it over and over from investors, “I wish I had bought Amazon or Netflix when they were first recommended by the Motley Fool. I’d be sitting on a gold mine!” And it’s true.

And while Amazon and Netflix have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $49 a share!

You can grab a copy of “5 Growth Stocks Under $49” for FREE for a limited time only.

Click here to learn more.

Learn more


Motley Fool Returns
STOCK ADVISOR
S&P 500
567%
114%
Stock Advisor launched in February of 2002. Returns as of 01/06/2021.

Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return
Motley Fools Stock Advisor has out performed the market by over 200% over the last 18 years
STOCKS
OPK
OPKO Health, Inc.
NASDAQ:OPK
$4.39up$0.14(3.41%)
RELATED ARTICLES
Why Opko Health Stock Jumped Today
2 Healthcare Stocks That Could Double Your Money
Why Opko Health Stock Is Tanking Today
Is OPKO Health Stock a Buy?

Talked to the IR person early December and she said the trail for Rayalde for corvid just started wonder when we see those results?

Please explain Thank you

I would hate to see the day if OPK ever had bad news!

Yes. The FDA must be behind because usually after a BLA it takes 60-90 for there decision

So the good news the FDA must not needed any more paperwork for the BLA.

This is the second week in a row I seen a Bio-Reference/OPKO commercial during a NFL football game I wonder who pays for it?

Talked to the company reason we have not heard from Bio-Reference is because they don't want the competition know who they are doing business with everyone went after the NFL once they announced the contract.

Interesting


https://www.google.com/amp/s/www.rochesterfirst.com/coronavirus/covid-testing-company-says-bills-stadium-model-could-work-for-restaurants/amp/

Watch not happening Pfizer will file the BLA by year end yes but Pfizer does not make that press release announcement on BLA"s

That news is not coming because Pfizer does not make BLA announcements they will announce if FDA receives there information and everything is good to file for approval which is 60 days after receiving the BLA

Probably just keeping SIAN happy by adding a board of director

Mednax (MD) stock hit a 5 yr. low in the summer. It was down nearly 80% from 2015 although they sold the radiology division recently. Stock has moved back up to $24 since it bottomed when Dr. Roger Medel retired

Roger Medel, M.D. appears to have a pretty solid background even if he is a friend of Frost's. He's 73 and net worth is around $79 million. He's highly paid, but he also founded MEDNAX where he recently retired. He looks more credible than Japour and many of the other OPKO directors Frost appointed

Oh wow Thank you

What kinda prints 10,000 or 100,000??

Not sure you know but Pfizer does not announce BLA before approvals they only announce if the drug get's approved or doesn't. So I recommend we as shareholders really put the pressure on OPK to announce the Filing with Somatrogen even though Pfizer does not!!!

I think we are all getting inpatient because we all know the upside potential. All I can say is the company is in the best position ever with 2 straight quarters being profitable and a third on its way. They have 2 drugs in phase 3 so yes as hard as it is we need to be patient?

Per my last post if Robinhood starts buying we are going a lot Highier??

Here we go off to the races!!

Robinhood has Opko on 4 Stocks to BUY now:

https://www.streetinsider.com/dr/news.php?id=17684586

I agree just keeping you on your toes HA HA

Sounds good However How do you represent a $12 target price?

What's the next press release in 2020 should we look for?